Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. on July 25, 2016. The filing discloses corporate governance changes, specifically the election of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the election of Julian Adams, Ph.D., to the Company's Board of Directors as a Class I Director, with a term expiring at the 2018 annual meeting of stockholders. Dr. Adams brings significant experience from Infinity Pharmaceuticals, Millennium Pharmaceuticals, and other biopharmaceutical entities.
Guidance, Outlook, and Compensation
Management commentary is limited to the rationale for Dr. Adams' appointment and his professional background. No financial guidance or outlook is provided in this filing. The following compensatory arrangements were established for Dr. Adams:
- Stock Option: Granted a non-statutory stock option to purchase up to 30,000 shares of Common Stock.
- Exercise Price: $1.73 per share (closing price on the date of grant).
- Vesting Schedule: Four equal quarterly installments over twelve months, contingent on continued service.
- Cash Retainer: Annual cash retainer of $25,000 for service as a non-executive director.
- Indemnification: An indemnification agreement was entered into to cover certain expenses, including legal fees and judgments arising from his service.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 30,000 share option granted to Dr. Adams.
- Confirm the total annual cash compensation obligation of $25,000 for the new director.
- Review the attached indemnification agreement (Exhibit 10.11 referenced in prior filings) for specific liability limits.
- Check subsequent filings for any changes to the Board composition or director compensation policy.